Gossamer Bio (GOSS) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T15:12:20.275Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:12:20.275Z.

Quote observation: 2026-10-06T15:09:24.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -165,377,000
Quote market capitalization: 65,810,990
Total debt · period ending 2026-06-30: 39,103,000
Cash · period ending 2026-06-30: 41,148,000

FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

GOSS EBITDA Yield Metrics

EBITDA YIELD

N/A

GOSS Competitors' EBITDA Yield

GOSS

Gossamer Bio, Inc.

Current

Market Cap

$65.81M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CING

Cingulate Inc.

vs GOSS

Market Cap

$65.73M

EBITDA Yield

446.47%

TTM Avg

3466.62%

3Y Avg

3466.62%

5Y Avg

3466.62%

HRTX

Heron Therapeutics, Inc.

vs GOSS

Market Cap

$65.11M

EBITDA Yield

N/A

TTM Avg

0.88%

3Y Avg

0.88%

5Y Avg

0.88%

INCR

InterCure Ltd.

vs GOSS

Market Cap

$64.68M

EBITDA Yield

N/A

TTM Avg

13.59%

3Y Avg

8.25%

5Y Avg

8.86%

KLRS

Kalaris Therapeutics Inc

vs GOSS

Market Cap

$63.30M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALPS

Alps Group Inc

vs GOSS

Market Cap

$63.23M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CSBR

Champions Oncology, Inc.

vs GOSS

Market Cap

$68.08M

EBITDA Yield

0.39%

TTM Avg

3.41%

3Y Avg

4.41%

5Y Avg

3.27%

FBIO

Fortress Biotech, Inc.

vs GOSS

Market Cap

$68.43M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs GOSS

Market Cap

$61.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs GOSS

Market Cap

$60.95M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Gossamer Bio, Inc. (GOSS)	$65.81M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$65.73M	446.47%	3466.62%	3466.62%	3466.62%
Heron Therapeutics, Inc. (HRTX)vs ›	$65.11M	N/A	0.88%	0.88%	0.88%
InterCure Ltd. (INCR)vs ›	$64.68M	N/A	13.59%	8.25%	8.86%
Kalaris Therapeutics Inc (KLRS)vs ›	$63.30M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$63.23M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$68.08M	0.39%	3.41%	4.41%	3.27%
Fortress Biotech, Inc. (FBIO)vs ›	$68.43M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$61.52M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.95M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

GOSS EBITDA Yield Metrics

GOSS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics